Trial Profile
Efficacy and safety of inolimomab in combination with etanercept as a second line treatment for acute graft-versus-host disease (aGVHD).
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Aug 2015
Price :
$35
*
At a glance
- Drugs Inolimomab (Primary) ; Etanercept
- Indications Graft-versus-host disease
- Focus Therapeutic Use
- 03 Aug 2015 New trial record
- 14 Jun 2015 Results presented at the 20th Congress of the European Haematology Association.